U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06800092) titled 'Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment' on Jan. 15.
Brief Summary: This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
Study Start Date: Feb. 15
Study Type: INTERVENTIONAL
Condition:
Cancer
Intervention:
DRUG: Sildenafil
Sildenafil, 50mg, daily
Recruitment Status: RECRUITING
Sponsor: The University of Texas Medical Branch, Galveston
Published by HT Digital Content Services with permission from Health Daily Digest....